Michael B. Bracken
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michael B. Bracken has a total of 99 co-authors. Here are the top co-authors by number of shared publications:
Kathleen Belanger
Center for Perinatal, Pediatric and Environmental Epidemiology, Yale University School of Public Health, New Haven, CT
9 shared publications- Kathleen Belanger
Yale Center for Perinatal, Pediatric and Environmental Epidemiology, Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT, USA
5 shared publications Brian P. Leaderer
Center for Perinatal, Pediatric and Environmental Epidemiology of the Department of Epidemiology and Public Health and Department of Obstetrics and Gynecology, Yale University School of Medicine, New Haven, Connecticut; Department of Epidemiology, University of Iowa College of Public Health, Iowa City, Iowa; and Department of Environmental Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York
4 shared publications- Brian P. Leaderer
Yale Center for Perinatal, Pediatric and Environmental Epidemiology, Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT, USA
4 shared publications Elizabeth W. Triche
Department of Epidemiology, Brown University, Providence, RI
4 shared publications- Elizabeth W. Triche
Department of Epidemiology, School of Public Health, Brown University, Providence, USA.
4 shared publications
Latest Publications
- 1 November 2019
- Published by Elsevier in The Lancet Psychiatry
- Vol. 6 (11) , 893
SSRIs and autism: interpreting an umbrella review
- 1 November 2019
- Published by Elsevier in The Lancet Psychiatry
- Vol. 6 (11) , 893
SSRIs and autism: interpreting an umbrella review
- 2 July 2019
- Published by American Medical Association (AMA) in JAMA
- Vol. 322 (1) , 81
Random-Effects Assumption in Meta-analyses
To the Editor In the context of meta-analysis of clinical trials, Drs Serghiou and Goodman outlined the differences between random-effects and fixed-effect mode
- 2 July 2019
- Published by American Medical Association (AMA) in JAMA
- Vol. 322 (1) , 81
Random-Effects Assumption in Meta-analyses
To the Editor In the context of meta-analysis of clinical trials, Drs Serghiou and Goodman outlined the differences between random-effects and fixed-effect mode
- Open Access
Updating Insights into Rosiglitazone and Cardiovascular Risk through Shared Data: Individual Patient- and Summary-Level Meta-Analyses
Objective: To conduct a systematic review and meta-analysis of the effects of rosiglitazone therapy on cardiovascular risk and mortality using multiple data sources and varying analytical approaches. Design: Systematic review and meta-analysis of randomized controlled trials. Data sources: GlaxoSmithKline’s (GSK) Clinical Study Data Request (CSDR) and Study Register platforms, MEDLINE, PubMed, Embase, Web of Science, Cochrane Central Registry of Controlled Trials, Scopus, and ClinicalTrials.gov from inception to January 2019. Study selection criteria: Randomized, controlled, phase II-IV clinical trials comparing rosiglitazone with any control for at least 24 weeks in adults. Data extraction and synthesis: For analyses of trials for which individual patient-level data (IPD) were available, we examined a composite of the following events as our primary outcome: acute myocardial infarction, heart failure, cardiovascular-related deaths, and non-cardiovascular-related deaths. As secondary analyses, these four events were examined independently. When also including trials for which IPD were not available, we examined myocardial infarction and cardiovascular-related deaths, ascertained from summary-level data. Multiple meta-analyses were conducted, accounting for trials with zero events in one or all arms with two different continuity corrections (i.e., 0.5 constant and treatment arm comparator continuity correction), to calculate odds ratios and risk ratios with 95% confidence intervals. Results: There were 33 eligible trials for which IPD were available (21156 participants) through GSK’s CSDR. We also identified 103 additional trials for which IPD were not available from which we ascertained myocardial infarctions (23683 patients) and 103 trials for cardiovascular-related deaths (22772 patients). Among trials for which IPD were available, we identified a greater number of myocardial infarctions and fewer cardiovascular-related deaths reported in the IPD as compared to the summary-level data. When limited to trials for which IPD were available and accounting for trials with zero-events in only one arm using a constant continuity correction of 0.5, patients treated with rosiglitazone had a 39% increased risk of a composite event compared with controls (Mantel-Haenszel odds ratio 1.39, 95% CI 1.15 to 1.68). When examined separately, the odds ratios for myocardial infarction, heart failure, cardiovascular-related death, and non-cardiovascular-related death were 1.25 (0.99 to 1.60), 1.60 (1.20 to 2.14), 1.18 (0.64 to 2.17), and 1.13 (0.58 to 2.20), respectively. When all trials for which IPD were and were not available were combined for myocardial infarction and cardiovascular-related deaths, the odds ratios were attenuated (1.13 (0.92 to 1.38) and 1.10 (0.73 to 1.65), respectively). Effect estimates and 95% confidence intervals were broadly consistent when analyses were repeated including trials with zero events across all arms using constant continuity corrections of 0.5 or treatment arm continuity corrections. Conclusions: Results of this comprehensive meta-analysis aggregating a multitude of trials and analyzed using a variety of statistical techniques suggest that rosiglitazone is consistently associated with an increased cardiovascular risk, likely driven by heart failure events, whose interpretation is complicated by varying magnitudes of myocardial infarction risk that were attenuated through aggregation of summary-level data in addition to IPD. Systematic review registration: https://osf.io/4yvp2/ What is already known on this topic: - Since 2007, there have been multiple meta-analyses, using various analytic approaches, that have reported conflicting findings related to rosiglitazone’s cardiovascular risk. - Previous meta-analyses have relied primarily on summary-level data, and did not have access to individual patient-level data (IPD) from clinical trials. - Currently, there is little consensus on which method should be used to account for sparse adverse event data in meta-analyses. What this study adds: - Among trials for which IPD were available, rosiglitazone use was consistently associated with an increased cardiovascular risk, likely driven by heart failure events. - Interpretation of rosiglitazone’s cardiovascular risk is complicated by varying magnitudes of myocardial infarction risk that were attenuated through aggregation of summary-level data in addition to IPD. - Among trials for which IPD were available, we identified a greater number of myocardial infarctions and fewer cardiovascular deaths reported in the IPD as compared to the summary-level data, which suggests that IPD may be necessary to accurately classify all adverse events when performing meta-analyses focused on safety.
Open AccessUpdating Insights into Rosiglitazone and Cardiovascular Risk through Shared Data: Individual Patient- and Summary-Level Meta-Analyses
Objective: To conduct a systematic review and meta-analysis of the effects of rosiglitazone therapy on cardiovascular risk and mortality using multiple data sources and varying analytical approaches. Design: Systematic review and meta-analysis of randomized controlled trials. Data sources: GlaxoSmithKline’s (GSK) Clinical Study Data Request (CSDR) and Study Register platforms, MEDLINE, PubMed, Embase, Web of Science, Cochrane Central Registry of Controlled Trials, Scopus, and ClinicalTrials.gov from inception to January 2019. Study selection criteria: Randomized, controlled, phase II-IV clinical trials comparing rosiglitazone with any control for at least 24 weeks in adults. Data extraction and synthesis: For analyses of trials for which individual patient-level data (IPD) were available, we examined a composite of the following events as our primary outcome: acute myocardial infarction, heart failure, cardiovascular-related deaths, and non-cardiovascular-related deaths. As secondary analyses, these four events were examined independently. When also including trials for which IPD were not available, we examined myocardial infarction and cardiovascular-related deaths, ascertained from summary-level data. Multiple meta-analyses were conducted, accounting for trials with zero events in one or all arms with two different continuity corrections (i.e., 0.5 constant and treatment arm comparator continuity correction), to calculate odds ratios and risk ratios with 95% confidence intervals. Results: There were 33 eligible trials for which IPD were available (21156 participants) through GSK’s CSDR. We also identified 103 additional trials for which IPD were not available from which we ascertained myocardial infarctions (23683 patients) and 103 trials for cardiovascular-related deaths (22772 patients). Among trials for which IPD were available, we identified a greater number of myocardial infarctions and fewer cardiovascular-related deaths reported in the IPD as compared to the summary-level data. When limited to trials for which IPD were available and accounting for trials with zero-events in only one arm using a constant continuity correction of 0.5, patients treated with rosiglitazone had a 39% increased risk of a composite event compared with controls (Mantel-Haenszel odds ratio 1.39, 95% CI 1.15 to 1.68). When examined separately, the odds ratios for myocardial infarction, heart failure, cardiovascular-related death, and non-cardiovascular-related death were 1.25 (0.99 to 1.60), 1.60 (1.20 to 2.14), 1.18 (0.64 to 2.17), and 1.13 (0.58 to 2.20), respectively. When all trials for which IPD were and were not available were combined for myocardial infarction and cardiovascular-related deaths, the odds ratios were attenuated (1.13 (0.92 to 1.38) and 1.10 (0.73 to 1.65), respectively). Effect estimates and 95% confidence intervals were broadly consistent when analyses were repeated including trials with zero events across all arms using constant continuity corrections of 0.5 or treatment arm continuity corrections. Conclusions: Results of this comprehensive meta-analysis aggregating a multitude of trials and analyzed using a variety of statistical techniques suggest that rosiglitazone is consistently associated with an increased cardiovascular risk, likely driven by heart failure events, whose interpretation is complicated by varying magnitudes of myocardial infarction risk that were attenuated through aggregation of summary-level data in addition to IPD. Systematic review registration: https://osf.io/4yvp2/ What is already known on this topic: - Since 2007, there have been multiple meta-analyses, using various analytic approaches, that have reported conflicting findings related to rosiglitazone’s cardiovascular risk. - Previous meta-analyses have relied primarily on summary-level data, and did not have access to individual patient-level data (IPD) from clinical trials. - Currently, there is little consensus on which method should be used to account for sparse adverse event data in meta-analyses. What this study adds: - Among trials for which IPD were available, rosiglitazone use was consistently associated with an increased cardiovascular risk, likely driven by heart failure events. - Interpretation of rosiglitazone’s cardiovascular risk is complicated by varying magnitudes of myocardial infarction risk that were attenuated through aggregation of summary-level data in addition to IPD. - Among trials for which IPD were available, we identified a greater number of myocardial infarctions and fewer cardiovascular deaths reported in the IPD as compared to the summary-level data, which suggests that IPD may be necessary to accurately classify all adverse events when performing meta-analyses focused on safety.
- 23 March 2016
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 81 (6) , 1191-1193
Meta‐analysis requires independent observations and freedom from bias
- 23 March 2016
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 81 (6) , 1191-1193
Meta‐analysis requires independent observations and freedom from bias
- 30 October 2015
- Published by Springer Nature in European Journal of Epidemiology
- Vol. 30 (11) , 1217-8
Case-control studies require appropriate population controls: an example of error in the SSRI birth defect literature.
- 30 October 2015
- Published by Springer Nature in European Journal of Epidemiology
- Vol. 30 (11) , 1217-8
Case-control studies require appropriate population controls: an example of error in the SSRI birth defect literature.
- 1 January 2015
- Published by Elsevier in Annals of Epidemiology
- Vol. 25 (1) , 46-54.e3
Low-to-moderate prenatal alcohol consumption and the risk of selected birth outcomes: a prospective cohort study
- 1 January 2015
- Published by Elsevier in Annals of Epidemiology
- Vol. 25 (1) , 46-54.e3
Low-to-moderate prenatal alcohol consumption and the risk of selected birth outcomes: a prospective cohort study
- 1 May 2014
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 70 (5) , 847-857.e18
The association of indoor tanning and melanoma in adults: Systematic review and meta-analysis
- 1 May 2014
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 70 (5) , 847-857.e18
The association of indoor tanning and melanoma in adults: Systematic review and meta-analysis
- 1 March 2014
- Published by Elsevier in Annals of Epidemiology
- Vol. 24 (3) , 171-173
Epidemiology as a liberal art: from graduate school to middle school, an unfulfilled agenda
- 1 March 2014
- Published by Elsevier in Annals of Epidemiology
- Vol. 24 (3) , 171-173
Epidemiology as a liberal art: from graduate school to middle school, an unfulfilled agenda
- Open Access
- 19 February 2014
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 6 (224) , 224cm1
Making Prospective Registration of Observational Research a Reality
Key information about human observational studies should be publicly available before the study is initiated.
- 19 February 2014
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 6 (224) , 224cm1
Open AccessMaking Prospective Registration of Observational Research a Reality
Key information about human observational studies should be publicly available before the study is initiated.
- Open Access
- 15 February 2014
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 43 (5) , 596-597
Re‐analysis of the PREGNANT trial confirms that vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix
- 15 February 2014
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 43 (5) , 596-597
Open AccessRe‐analysis of the PREGNANT trial confirms that vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix